WHO Pharmaceuticals Newsletter 2003, No. 03
(2003; 14 pages) View the PDF document
Table of Contents
View the documentACETYLSALICYLIC ACID - MHRA confirms labelling change
View the documentACITRETIN - Warnings of depression added to label
View the documentASTEMIZOLE - Withdrawn due to life-threatening ventricular arrhythmias
View the documentCAMELIA SINENSIS - Ethanolic extract products withdrawn due to hepatotoxicity
View the documentDIETARY SUPPLEMENTS - Withdrawal of two products due to presence of sildenafil
View the documentHUA FO - Presence of tadalafil
View the documentIODINE - Some products contain more than the RDA
View the documentLEVODOPA/CARBIDOPA - New warning about somnolence and sudden onset sleep
View the documentLINDANE - Additional warnings and medication guide added to label
View the documentNEFAZODONE - Regulatory status update
View the documentNIMESULIDE - Paediatric preparations banned in Bangladesh
View the documentPERGOLIDE MESYLATE - Risk of cardiac valvulopathy
View the documentREPAGLINIDE - Contraindicated with gemfibrozil
View the documentRISPERIDONE - Prescribing information updated to reflect cardiovascular adverse events
View the documentTELITHROMYCIN - Aggravation of myasthenia gravis
Open this folder and view contentsSAFETY OF MEDICINES
Open this folder and view contentsCURRENT CONCERNS
Open this folder and view contentsDRUGS OF INTEREST
Open this folder and view contentsFEATURE

LINDANE - Additional warnings and medication guide added to label

USA. The US FDA has issued a Public Health Advisory concerning the use of topical formulations of lindane lotion or shampoo for the treatment of scabies and lice, which announces significant updates to the product labelling. The labelling changes include the addition of a new boxed warning which emphasises that lindane is only indicated as a second-line treatment for scabies and lice in patients who are intolerant of, or unresponsive to, other therapies. It also provides updated safety information regarding the potential risks of adverse effects associated with use and misuse of the products, and states that lindane lotion or shampoo is contraindicated in premature infants, is not recommended for use in infants and should be used with caution in patients who weigh less than 50kg (110 pounds). The new warning also advises practitioners that, if itching continues after a single treatment, reapplication of lindane lotion or shampoo is not appropriate. The advisory states that lindane packaging sizes will be limited to 1 and 2 ounces to minimise the potential for patients to apply the product in excess and to minimise reapplication, and that pharmacists should only dispense sufficient lindane for a single application (< 2 fluid ounces). A medication guide informing patients of the risks associated with lindane products and providing instructions for the appropriate use of the drug must now be dispensed by the pharmacist with each new prescription.

FDA Talk Paper, 28 March 2003. Available from URL: http://www.fda.gov

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018